We are live on ! Find out more
PSNL icon

Personalis

67 hedge funds and large institutions have $156M invested in Personalis in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 39 increasing their positions, 7 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

457% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 7

5.62% more ownership

Funds ownership: 55.77%61.38% (+5.6%)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

14% less funds holding

Funds holding: 7867 (-11)

18% less capital invested

Capital invested by funds: $190M → $156M (-$33.6M)

45% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 20

Holders
67
Holders Change
-11
Holders Change %
-14.1%
% of All Funds
1.47%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.07%
New
11
Increased
39
Reduced
7
Closed
20
Calls
$222K
Puts
Net Calls
+$222K
Net Calls Change
-$45K

PSNL Hedge Fund Activity: Q1 2020 in Review

67 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Personalis (PSNL) for Q1 2020, worth a combined $156M — down 18% from $190M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of PSNL and 11 opened new positions — a net loss of 9 holders — while 7 trimmed existing stakes and 39 added.

The largest buyer was JP Morgan Chase, adding an estimated $4.94M. The largest seller was OrbiMed, exiting entirely with an estimated $5.27M sold.

  • 67 institutional investors held Personalis (PSNL) as of Q1 2020, down from 78 in Q4 2019.
  • Funds reported $156M of Personalis stock for Q1 2020, down 18% quarter-over-quarter.
  • 11 funds opened new Personalis positions in Q1 2020 and 20 closed out, a net change of -9 holders.
  • The largest Personalis buyer in Q1 2020 was JP Morgan Chase, an estimated $4.94M added.
  • The largest Personalis seller in Q1 2020 was OrbiMed, an estimated $5.27M sold.

Based on aggregated 13F filings for Q1 2020.